Get the Stockscreener App
23.47
6.12%
-1.53
After Hours:
23.55
0.08
+0.34%
Travere Therapeutics Inc stock is traded at $23.47, with a volume of 2.94M.
It is down -6.12% in the last 24 hours and up +34.81% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$25.00
Open:
$24.765
24h Volume:
2.94M
Relative Volume:
1.60
Market Cap:
$2.09B
Revenue:
$333.87M
Net Income/Loss:
$-169.00M
P/E Ratio:
-11.50
EPS:
-2.04
Net Cash Flow:
$-157.30M
1W Performance:
+8.46%
1M Performance:
+34.81%
6M Performance:
+21.80%
1Y Performance:
+86.27%
1-Day Range:
$23.20
$24.82
1-Week Range:
$20.84
$28.69
52-Week Range:
$12.57
$28.69
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
23.47 | 2.43B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Travere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGS (NASDAQ:TVTX) - Seeking Alpha
HC Wainwright Reaffirms Buy Rating for Travere Therapeutics (NASDAQ:TVTX) - MarketBeat
TVTX: Stifel Raises Price Target to $25, Maintains Hold Rating | TVTX Stock News - GuruFocus
Travere Therapeutics (NASDAQ:TVTX) Reaches New 1-Year HighHere's What Happened - MarketBeat
Travere Therapeutics, Inc. $TVTX Shares Sold by Parkman Healthcare Partners LLC - MarketBeat
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 11, 2025 - BioSpace
Jacobs Levy Equity Management Inc. Decreases Stock Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
Polar Asset Management Partners Inc. Invests $304,000 in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA - sharewise.com
Travere Therapeutics (TVTX) Stock Decline Amid Market Activity - GuruFocus
Wells Fargo Raises Price Target for Travere Therapeutics (TVTX) to $35.00 | TVTX Stock News - GuruFocus
H.C. Wainwright reiterates buy rating on Travere Therapeutics stock By Investing.com - Investing.com Canada
Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside - Insider Monkey
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength? - Yahoo Finance
FDA Drops Advisory Committee for Travere’s FILSPARI Review - MSN
Analysts Set Travere Therapeutics, Inc. (NASDAQ:TVTX) Target Price at $33.43 - MarketBeat
Travere rises as FDA says no AdCom required for Filspari label expansion - MSN
Travere Therapeutics stock hits 52-week high at 25.33 USD - Investing.com India
Top 4% Biotech Hits Three-Year High On An FDA Surprise - Investor's Business Daily
Travere Shares Are Trading Higher Wednesday: What's Going On? - Benzinga
TVTX: HC Wainwright & Co. Reiterates Buy Rating and Price Target - GuruFocus
Travere: No AdCom, No ProblemTargeting Big Revenues With FSGS Approval (NASDAQ:TVTX) - Seeking Alpha
Investors Buy Large Volume of Travere Therapeutics Call Options (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics stock jumps as FDA cancels advisory committee for Filspari - Investing.com Canada
Travere Therapeutics stock hits 52-week high at 25.33 USD By Investing.com - Investing.com Nigeria
Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High - MSN
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for Filspari® in Focused Segmental Glomerulosclerosis - MarketScreener
Travere Therapeutics (TVTX) Rises as FDA Review Progresses Witho - GuruFocus
Travere Therapeutics provides update on FDA advisory committee meeting for Filspari in FSGS - MarketScreener
FDA no longer requires advisory committee for Travere’s FSGS drug - Investing.com
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS - The Globe and Mail
Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application - Stocktwits
Trexquant Investment LP Trims Stock Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. $TVTX Shares Bought by Northern Trust Corp - MarketBeat
Adage Capital Partners GP L.L.C. Grows Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
RSI Crosses Above 30 for Travere Therapeutics Inc. — Reversal in Sight2025 Performance Recap & Safe Capital Allocation Plans - beatles.ru
Quant Models Detect Momentum Reversal in Travere Therapeutics Inc.2025 Major Catalysts & Expert Verified Movement Alerts - beatles.ru
Chart based analysis of Travere Therapeutics Inc. trends2025 Geopolitical Influence & Intraday High Probability Alerts - Newser
Travere Therapeutics (NASDAQ:TVTX) Shares Up 5% on Analyst Upgrade - MarketBeat
Identifying reversal signals in Travere Therapeutics Inc.July 2025 Analyst Calls & Advanced Technical Analysis Signals - Newser
Improved Revenues Required Before Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock's 26% Jump Looks Justified - simplywall.st
Is Travere Therapeutics Inc. a good ESG investmentJuly 2025 Setups & Reliable Intraday Trade Alerts - خودرو بانک
Travere Therapeutics Inc. stock trend forecastWeekly Trade Summary & Weekly Hot Stock Watchlists - Newser
How sensitive is Travere Therapeutics Inc. to inflation2025 Analyst Calls & Daily Entry Point Trade Alerts - خودرو بانک
PDT Partners LLC Acquires 62,425 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
What is Travere Therapeutics Inc.’s book value per share2025 Market Overview & Smart Swing Trading Techniques - خودرو بانک
Can Travere Therapeutics Inc. lead its sector in growthPortfolio Performance Report & Long-Term Capital Growth Ideas - خودرو بانک
Can Travere Therapeutics Inc. rally from current levels2025 Analyst Calls & Smart Allocation Stock Reports - Newser
Does Travere Therapeutics Inc. stock have upside surprise potentialMarket Growth Review & Fast Entry High Yield Tips - خودرو بانک
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):